atorvastatin has been researched along with Vascular Calcification in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Liang, Z; Nie, M; Yan, Y; Zhang, X; Zhao, Q | 1 |
| Assali, M; Berus, JM; Ceneri, N; Choudhary, G; Christensen, JL; Dong, W; Healy, A; Lee, C; Mantsounga, C; Morrison, AR; Neverson, J; Nilson, R; Watts, JP; Wu, WC | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Cui, W; Gu, G; Hu, H; Liu, B; Liu, D; Liu, J; Xie, R; Yang, X; Zhang, J; Zheng, H | 1 |
| Aguirre, B; Alvarez-Gago, T; Bratos, MA; Cenizo Revuelta, N; Gonzalez-Fajardo, JA; Vaquero, C | 1 |
| Blumenthal, RS; Greenland, P; Polonsky, TS | 1 |
| Aldhamy, SE; Elsawy, MM; Elseweidy, MM; Saeid, SA; Zein, N | 1 |
| Cao, JJ; Guerci, A; Pollack, S; Reichek, N; Roth, M; Waheed, S | 1 |
| Chen, MF; Chi, YC; Huang, CL; Huang, PJ; Kao, HL; Lin, HJ; Lin, LY; Lin, YH; Tzen, KY; Wang, YC; Wu, YW; Yang, WS; Yen, RF | 1 |
| Hacker, M | 1 |
| Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES | 1 |
| Villines, TC | 1 |
4 trial(s) available for atorvastatin and Vascular Calcification
| Article | Year |
|---|---|
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
Topics: Aged; Asymptomatic Diseases; Atorvastatin; Biomarkers; Comorbidity; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Prevalence; Primary Prevention; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2016 |
The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers.
Topics: Abdominal Fat; Adult; Aged; Anti-Inflammatory Agents; Arteritis; Atherosclerosis; Atorvastatin; Biomarkers; Calcium; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Pyrroles; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vascular Calcification | 2012 |
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2012 |
8 other study(ies) available for atorvastatin and Vascular Calcification
| Article | Year |
|---|---|
Atorvastatin Promotes Macrocalcification, But Not Microcalcification in Atherosclerotic Rabbits: An 18F-NaF PET/CT Study.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Calcium; Disease Models, Animal; Fluorine Radioisotopes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Rabbits; Radiopharmaceuticals; Sodium Fluoride; Vascular Calcification | 2021 |
Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification.
Topics: Aged; Animals; Atherosclerosis; Atorvastatin; Cells, Cultured; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Macrophages; Male; Mice, Knockout, ApoE; Neuropeptides; Plaque, Atherosclerotic; Prenylation; rac1 GTP-Binding Protein; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Retrospective Studies; rho Guanine Nucleotide Dissociation Inhibitor alpha; Signal Transduction; Vascular Calcification | 2020 |
Atorvastatin protects vascular smooth muscle cells from TGF-β1-stimulated calcification by inducing autophagy via suppression of the β-catenin pathway.
Topics: Animals; Atorvastatin; Autophagy; beta Catenin; Cytoprotection; Down-Regulation; Male; Models, Biological; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta1; Vascular Calcification | 2014 |
Role of calcifying nanoparticle in the development of hyperplasia and vascular calcification in an animal model.
Topics: Angioplasty, Balloon; Animals; Atorvastatin; Calcifying Nanoparticles; Carotid Arteries; Carotid Artery Injuries; Carotid Intima-Media Thickness; Cholesterol; Disease Models, Animal; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Male; Muscle, Smooth, Vascular; Neointima; Pyrroles; Rabbits; Time Factors; Triglycerides; Vascular Calcification | 2014 |
Coronary artery calcium score.
Topics: Atorvastatin; Calcium; Cardiovascular Diseases; Coronary Vessels; Diet; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Middle Aged; Pyrroles; Risk; Tomography, X-Ray Computed; Vascular Calcification | 2014 |
Policosanol as a new inhibitor candidate for vascular calcification in diabetic hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Calcification, Physiologic; Diabetes Mellitus, Experimental; Diet, High-Fat; Fatty Acids, Omega-3; Fatty Alcohols; Hyperlipidemias; Male; Oxidative Stress; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Vascular Calcification | 2016 |
Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice.
Topics: Abdominal Fat; Anti-Inflammatory Agents; Arteritis; Atorvastatin; Female; Heptanoic Acids; Humans; Male; Pyrroles; Vascular Calcification | 2012 |
Statin therapy for subclinical atherosclerosis in primary prevention: time to prove it?
Topics: Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrroles; Vascular Calcification | 2012 |